Key facts
- This page summarizes Darren Joel Patti's Form 3 filing for Telix Pharmaceuticals Ltd (TLX).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2026, 07:24.
Darren Joel Patti - 18 Mar 2026 Form 3 Insider Report for Telix Pharmaceuticals Ltd (TLX)
- Reporting relationship
- Group Chief Operating Officer
- Issuer ticker
- TLX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Oliver Newman, on behalf of Dr. Darren Patti, Group COO
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Darren Joel Patti filed Form 3 for Telix Pharmaceuticals Ltd (TLX) on 01 Apr 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002122492
Primary reporting owner
Patti Darren Joel
- Relationship
- Group Chief Operating Officer
- Address
- C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
- Signature
- /s/ Oliver Newman, on behalf of Dr. Darren Patti, Group COO
- Signature date
- 01 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,558
- Date
- 18 Mar 2026
- Ownership
- Direct
TLX
holding
American Depositary Receipts
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 804
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLX
holding
Derivative
Performance Share Appreciation Rights (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 15,826
- Exercise price
- $4.95
- Footnotes
- F2, F3
TLX
holding
Derivative
Share Rights
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 15,000
- Exercise price
- $0.000000
- Footnotes
- F4
TLX
holding
Derivative
Share Rights
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 12,541
- Exercise price
- $0.000000
- Footnotes
- F5
TLX
holding
Derivative
Performance Share Appreciation Rights (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 27,448
- Exercise price
- $6.90
- Footnotes
- F3, F6
TLX
holding
Derivative
Share Rights
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 15,000
- Exercise price
- $0.000000
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date.
Footnote F2
The performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and excercisable on March 6, 2025.
Footnote F3
Conversion price is reported in Australian Dollars.
Footnote F4
The share rights (SRs) were granted on November 1, 2023 and will become vested and exercisable on November 1, 2026, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.
Footnote F5
The SRs were granted on March 18, 2026 and will become auto-vested and exercised in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share (or ADR). See footnote (1).
Footnote F6
The PSARs were granted on May 2, 2023, and became vested and exercisable on March 12, 2026.
Footnote F7
The SRs were granted on November 1, 2023 and will become vested and exercisable on November 1, 2027, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.
SEC remarks
Ex. 24 - Power of Attorney